Cancer Research UK unveil new Chief Business Officer
pharmafile | June 8, 2018 | News story | Medical Communications | Cancer Research UK, biotech, drugs, pharma, pharmaceutical
Cancer Research UK has appointed Tony Hickson to the position of Chief Business Officer. He arrives to the business from his position as Managing Director of Technology Transfer at Imperial Innovations, the technology transfer office of Imperial College London (ICL).
Hickson will begin his role in August, with his role dedicated to driving forward the commercial interests of the charity.
In his previous position within the IP Group, where he held a position as member of the executive committee, he was active in fundraising and in fostering industry collaborations.
Hickson was also involved in the $466 million hostile takeover of Touchstone, after the latter had previously rejected an approach from IP Group as it deemed the offer to undervalue the company. He had previously been an Executive Director for Touchstone but left the position after the completion of the deal.
Prior to these positions, he worked at Abbott, as a Licensing Executive, and at the Wellcome Group.
Dr Iain Foulkes, Cancer Research UK’s executive director of research and innovation, said: “We’re thrilled to welcome Tony Hickson as our new chief business officer. Tony will be a huge asset to the charity, bringing great experience and ambition to our research and innovation activities.”
He continued, “Commercial development of our research is a key route through which Cancer Research UK ensures the most promising scientific discoveries are translated into urgently needed new treatments, diagnostics and technologies for patients with cancer.”
Cancer Research UK made note that Hickson had been involved in a series of spin-outs from ICL, with a combined value of over £500 million.
Hickson said, “I’m delighted to join Cancer Research UK at such an exciting time for the charity’s commercial development. I look forward to taking a lead role in the planned expansion of the charity’s commercialisation activity, building a hub for strategic research innovation, welcoming new partners and strengthening our relationships with industry.”
Ben Hargreaves
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Zumutor’s cancer drug trial cleared by FDA
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …
